Asahi Intecc (7747) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
13 Nov, 2026Executive summary
Q1 FY2027 net sales rose 21.3% YoY to ¥43,729 million; operating profit increased 34.8% to ¥17,569 million, and profit attributable to owners of parent rose 38.0% to ¥12,706 million.
Sales increased in both divisions and quarterly performance exceeded plan; FY2027 guidance remained unchanged pending review of distributor timing, FX and expense recognition.
Financial highlights
Gross profit increased 27.0% YoY to ¥32,307 million; gross margin rose to 73.9% from 70.5%.
Ordinary profit rose 39.0% to ¥17,909 million; basic EPS increased to ¥47.89 from ¥34.37.
Comprehensive income decreased 16.1% to ¥9,896 million, mainly due to a smaller foreign-currency translation adjustment.
SG&A rose to ¥14,737 million from ¥12,401 million; its sales ratio declined to 33.7% from 34.3%, and R&D expense was ¥3,252 million.
Outlook and guidance
FY2027 forecast unchanged: net sales ¥161,794 million, operating profit ¥52,127 million, ordinary profit ¥52,600 million and parent-attributable profit ¥37,832 million.
FY2027 basic EPS forecast is ¥142.59; Q1 sales and profit exceeded plan, but full-year effects of distributor timing, FX and expense recognition remain under review.
SG&A timing differences, mainly R&D expenses, affected Q1; expenses are expected to progress generally as planned for FY2027.
Latest events from Asahi Intecc
- Raising 2030 targets, the plan accelerates global growth in high value-added medical devices.7747
Corporate presentation - Strong sales and profit growth driven by Medical and Device divisions and overseas demand.7747
Q4 2026 - Operating profit up 45.5% and net income up 204.2% year-over-year, with strong outlook.7747
Q3 2026 - Operating profit up 40.1% and EPS up 43.0% on strong sales and margin gains.7747
Q2 2026 - Strong sales and profit growth, with improved margins and some European market uncertainty.7747
Q1 2026 - Strong sales and profit growth led by Medical, but net income declined on impairment losses.7747
Q4 2025 - Medical Division growth and margin gains drove strong profit increases; outlook steady.7747
Q1 2025 - Record revenue and profit growth, with strong Medical Division performance and robust outlook.7747
Q4 2024 - Strong sales and operating profit growth offset by major impairment losses.7747
Q3 2025